2seventy bio Reports Strong Q3 with Abecma Growth

The latest announcement is out from 2seventy bio ( (TSVT) ).

2seventy bio reported impressive third-quarter results with a 42% increase in Abecma sales, driven by expanding its use in early treatment lines for multiple myeloma. The company achieved significant cost reductions and ended the quarter with a net loss of $10 million, while maintaining a strong cash position of $192 million, expected to sustain them beyond 2027. 2seventy bio remains focused on Abecma’s safety and efficacy, aiming to expand its reach in the competitive multiple myeloma market.

Learn more about TSVT stock on TipRanks’ Stock Analysis page.